Epstein-Barr Virus DNA Loads in Adult Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy

Paul D. Ling, Regis A. Vilchez, Wendy A. Keitel, David G. Poston, Rong Sheng Peng, Zoe S. White, Fehmida Visnegarwala, Dorothy E. Lewis, Janet S. Butel

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Patients with human immunodeficiency virus type 1 (HIV-1) infection are at high risk of developing Epstein-Barr virus (EBV)-associated lymphoma. However, little is known of the EBV DNA loads in patients receiving highly active antiretroviral therapy (HAART). Using a real-time quantitative polymerase chain reaction assay, we demonstrated that significantly more HIV-1-infected patients receiving HAART than HIV-1-uninfected volunteers had detectable EBV DNA in blood (57 [81%] of 70 vs. 11 [16%] of 68 patients; P = .001) and saliva (55 [79%] of 68 vs. 37 [54%] of 68 patients; P = .002). The mean EBV loads in blood and saliva samples were also higher in HIV-1-infected patients than in HIV-1-uninfected volunteers (P = .001). The frequency of EBV detection in blood was associated with lower CD4+ cell counts (P = .03) among HIV-1-infected individuals, although no differences were observed in the EBV DNA loads in blood or saliva samples in the HIV-1-infected group. Additional studies are needed to determine whether EBV-specific CD4+ and CD8+ cells play a role in the pathogenesis of EBV in HIV-1-infected patients receiving HAART.

Original languageEnglish (US)
Pages (from-to)1244-1249
Number of pages6
JournalClinical Infectious Diseases
Volume37
Issue number9
DOIs
StatePublished - Nov 1 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Epstein-Barr Virus DNA Loads in Adult Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy'. Together they form a unique fingerprint.

Cite this